Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.

• Conditions: Rare Disease With Poor Outcome

• Registration Number: NCT05347511
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Primary Central Nervous System Lymphoma (PCNSL) have a specific mutational profile in comparison to systemic diffuse large cells lymphoma (DLBCLs) that can be related to the expression of immunohistochemical markers as cyclon, NPM1, CD30, and P53 which could be predictive factor for prognosis and/or chemotherapy response. The main objective of this study is to identify new prognostic factors and new potential therapeutic targets.

The secondary objectives are to correlate the histological, the radiological and the clinical's informations of these patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-04
• Study Start: 2022-04-20
• Study First Submitted: 2022-04-20
• Study First Submitted QC: 2022-04-20
• Last Update Submitted: 2022-04-20
• Study First Posted: 2022-04-26
• Last Update Posted: 2022-04-26
• Primary Completion: 2022-09-01
• Study Completion: 2022-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 94

Inclusion Criteria

• PCNSL diagnosed between January 2011 and December 2019, without regard to the clinical outcome.
• Age > 18

Exclusion Criteria

• Systemic DLBCL

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
correlation between the survival and the expression of Cyclon, NPM1 and CD30.	17/10/2022	kaplan meyer

Secondary Outcome Measures

Name	Time	Method
the correlation between the molecular abnormalities and the expression of Cyclon, NPM1 and CD30	17/10/2022	mutational signature